Novartis renews its organization chart. The pharmaceutical company will integrate the pharmaceutical and oncology business units, and will create two separate business organizations with a specific geographic focus.
One of them will be totally focused on sales in the United States, which is part of the line of becoming one of the top five companies in the country. On the other hand, Marie-France Tschudin, president of Novartis, will become president and commercial director of the international sales unit.
Tschudin will oversee global marketing, medical affairs and access to all therapeutic areas. For his part, Víctor Bulto, director of pharmaceutical products in the United States, will become president of the area of innovative medicines in this country.
Novartis will also create a new area of strategy and growth, which will combine the corporate strategy, research and development (R&D) portfolio strategy and business development. This area is intended to help drive the company’s growth strategy throughout all stages and will analyze opportunities to strengthen the product portfolio.
Novartis will also create a new strategy and growth function
With this reform, the Swiss pharmaceutical company has a new organizational structure that aims to “support the ambitions of innovation, growth and productivity for the next decade”, as announced by the company in a statement.
“This organizational model is simpler and we see it as critical to our growth strategy as it will make us more agile and competitive, improve patient and customer focus, unlock significant potential in our R&D portfolio and drive the creation of value through operational efficiency”, explained Vas Narasimhan, CEO of Novartis.
–
